Tema Etfs LLC Acquires Shares of 798 Stryker Co. (NYSE:SYK)

Tema Etfs LLC acquired a new stake in Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 798 shares of the medical technology company’s stock, valued at approximately $287,000.

A number of other institutional investors have also recently bought and sold shares of the business. Elefante Mark B bought a new position in shares of Stryker during the 4th quarter worth $337,000. Chicago Capital LLC grew its stake in shares of Stryker by 3.1% during the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after acquiring an additional 5,841 shares during the period. Zhang Financial LLC grew its stake in shares of Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after acquiring an additional 40,784 shares during the period. Appleton Partners Inc. MA grew its stake in shares of Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock worth $10,521,000 after acquiring an additional 1,400 shares during the period. Finally, Metis Global Partners LLC grew its stake in shares of Stryker by 10.2% during the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after acquiring an additional 1,561 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $394.24 on Monday. The business’s 50-day moving average price is $366.62 and its two-hundred day moving average price is $375.61. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The stock has a market cap of $150.48 billion, a P/E ratio of 50.80, a PEG ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted $2.50 EPS. As a group, equities analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. Stryker’s dividend payout ratio is 45.41%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Roth Mkm increased their price target on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Canaccord Genuity Group increased their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Truist Financial increased their price objective on Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, May 5th. Royal Bank of Canada increased their price objective on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $427.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.